Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Prostate cancer

Enzalutamide impresses in European studies

Nature Reviews Urology volume 11, page 243 (2014)Cite this article

Subjects

Enzalutamide continues to extend its potential in men with prostate cancer. New data, published in the Lancet Oncology, suggest it might be a viable alternative to castration for patients with advanced disease, and subpopulation analysis of the PREVAIL study, presented at the European Association of Urology (EAU) annual meeting in Stockholm, confirms its benefit as first-line therapy for European patients with castration-resistant prostate cancer (CRPC).

The study published in the Lancet Oncology is a primary analysis of the first phase II trial of enzalutamide monotherapy in men with hormone-naive prostate cancer. Patients with advanced disease are usually treated with androgen deprivation therapy (ADT), which can be surgical (bilateral orchiectomy) or medical (with luteinising hormone-releasing hormone analogues), but these options are hampered by adverse effects caused by low testosterone levels, including sexual dysfunction, decreased bone mineral density and loss of muscle mass.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tombal, B. et al. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 10.1016/S1470-2045(14)70129-9

  2. Tombal, B. et al. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Primary and European regional results of the phase 3 prevail study [abstract LBA3]. Presented at the 29th Annual EAU Congress (Stockholm).

Download references

Authors
  1. Sarah Payton
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Payton, S. Enzalutamide impresses in European studies. Nat Rev Urol 11, 243 (2014). https://doi.org/10.1038/nrurol.2014.98

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2014.98

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing